Transcranial sonography in Huntington'S disease

International Review of Neurobiology

Volumn 90, Issue C, 2010, Pages 237-257

  Krogias, Christos ^a   Eyding, Jens ^a   Postert, Thomas ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b St Vincenz Hospital   (Germany)

Author keywords

Basal ganglia; Huntington's disease; Raphe; Transcranial sonography; Ultrasound; Westphal variant

Indexed keywords

ADENINE; CYTOSINE; GUANINE; HUNTINGTIN;

ARTICLE; BASAL GANGLION; BRAIN STEM; BRAIN THIRD VENTRICLE; CAG REPEAT; CAUDATE NUCLEUS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; HUNTINGTON CHOREA; IMAGE ANALYSIS; LATERAL BRAIN VENTRICLE; MENTAL DISEASE; MOLECULAR GENETICS; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROIMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS; SIGNAL DETECTION; SUBSTANTIA NIGRA; THALAMUS;

EID: 77955403095     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(10)90017-2     Document Type: Chapter

References (78)

1. Andrich J., Schmitz T., Saft C., Postert T., Kraus P., Epplen J.T., Przuntek H., Agelink M.W. Autonomic nervous system function in Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 2002, 72:726-731.
2. Andrich J., Arning L., Wieczorek S., Kraus P.H., Gold R., Saft C. Huntington's disease as caused by 34 CAG repeats. Mov. Disord. 2008, 23:879-881.
3. Aylward E.H., Sparks B.F., Field K.M., Yallapragada V., Shpritz B.D., Rosenblatt A., Brandt J., Gourley L.M., Liang K., Zhou H., Margolis R.L., Ross C.A. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
4. Bartzokis G., Tischler T.A. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol. Biol. 2000, 46:821-833.
5. Beck A.T., Ward C., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 1961, 4:561-571.
6. Becker G., Becker T., Struck M., Lindner A., Burzer K., Retz W., Bogdahn U., Beckmann H. Reduced echogenicity of brainstem raphe specific to unipolar depression: A transcranial color-coded real-time sonography study. Biol. Psychiatry. 1995, 38:180-184.
7. Becker G., Berg D., Lesch K.P., Becker T. Basal limbic system alteration in major depression: A hypothesis supported by transcranial sonography and MRI findings. Int. J. Neuropsychopharmacol. 2001, 4:21-31.
8. Becker G., Berg D., Rausch W.D., Lange H.K., Riederer P., Reiners K. Increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia. Ann. Neurol. 1999, 46:260-263.
9. Berg D., Becker G., Zeiler B., Tucha O., Hofmann E., Preier M., et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999, 53:1026-1031.
10. Berg D., Supprian T., Hofmann E., Zeiler B., Jäger A., Lange K.W., Reiners K., Becker T., Becker G. Depression in Parkinson's disease: Brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J. Neurol. 1999, 246:1186-1193.
11. Berg D., Siefker C., Ruprecht-Dorfler P., Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001, 56:13-17.
12. Berg D., Jabs B., Merschdorf U., Beckmann H., Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol. Psychiatry. 2001, 50:463-467.
13. Berg D., Roggendorf W., Schroder U., Klein R., Tatschner T., Benz P., et al. Echogenicity of the substantia nigra: Association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 2002, 56:999-1005.
14. Berg D., Godau J., Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008, 7:1044-1055.
15. Brinkmann R.R., Mezei M.M., Theilmann J., et al. The likelihood of being affected with Huntington's disease by a particular age, for a specific CAG size. Am. J. Hum. Genet. 1997, 60:1202-1210.
16. Brooks D.J., Frackowiak R.S.J. PET and movement disorders. J. Neurol. Neurosurg. Psychiatry. 1989, (Suppl):68-77.
17. Brouwers P., Cox C., Martin A., et al. Differential perceptual-spatial impairment in Huntington's and Alzheimer's disease. Arch. Neurol. 1984, 41:1073-1076.
18. Davies S.W., Turmaine M., Cozens B.A., et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997, 90:537-548.
19. DeLong M.R. The basal ganglia. Principles of Neural Science 2000, 853-867. McGraw-Hill, New York. Fourth Edition. E.R. Kandel, J.H. Schwartz (Eds.).
20. De Souza J., Jones L.A., Rickards H. Validation of self-report depression rating scales in Huntington's disease. Mov. Disord. 2009, Nov 11 Epub ahead of print.
21. Di Maio L., Squitieri F., Napolitano G., Campanella G., Trofatter J.A., Conneally P.M. Suicide risk in Huntington's disease. J. Med. Genet. 1993, 48:231-233.
22. Duff K., Paulsen J.S., Beglinger L.J., et al. Psychiatric symptoms in Huntington's disease before diagnosis: The predict-HD study. Biol. Psychiatry. 2007, 62:1341-1346.
23. Fennema-Notestine C., Archibald S.L., Jacobson M.W., Corey-Bloom J., Paulsen J.S., Peavy G.M., Gamst A.C., Hamilton J.M., Salmon D.P., Jernigan T.L. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004, 63:989-995.
24. Gargiulo M., Lejeune S., Tanguy M.L., Lahlou-Laforet K., Faudet A., Cohen D., Feingold J., Durr A. Long-term outcome of presymptomatic testing in Huntington disease. Eur. J. Hum. Gen. 2009, 17:165-171.
25. Grafton S.T., Sumi S.M., Stimac G.K., et al. Comparison of post-mortem magnetic resonance imaging and neuropathological findings in the cerebral white matter. Arch. Neurol. 1991, 48:293-298.
26. Hahn-Barma V., Deweer B., Dürr A., Dod C., Feingold J., Pillon B., Agid Y., Brice A., Dubois B. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. J. Neurol. Neurosurg. Psychiatry. 1998, 64:172-177.
27. Hamilton M. Development of a rating scale fpr primary depressive illness. Br. J. of. Soc. Clin. Psychology. 1967, 6:278-296.
28. Hayflick S.J., Harman M., Coryell J., Gitschier J., Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. Am. J. Neuroradiol. 2006, 27:1230-1233.
29. Hennenlotter A., Schroeder U., Erhard P., Haslinger B., Weindl A., Stahl, von Einsiedel H.G., Lange K.W., Ceballos-Baumann A.O. Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease. Brain 2004, 127:1446-1453.
30. Hilditch-Maguire P., Trettel F., Passani L.A., Auerbach A., Persichetti F., MacDonald M.E. Huntingtin: An iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 2000, 9:2789-2797.
31. Ho A.K., Sahakian B.J., Brown R.G., et al. Profile of cognitive progression in early Huntington's disease. Neurology 2003, 61:1702-1706.
32. Ho V.B., Chuang S., Rovira M.J., Koo B. Juvenile Huntington Disease: CT and MR features. Am. J. Neuroradiol. 1995, 16:1405-1412.
33. Huckmann M.S., Fox J., Topel J. The validity of criteria for the evaluation of cerebral atrophy by computed tomography. Radiology. 1975, 116:85-92.
34. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72:971-983. Huntington's Disease Collaborative Research Group.
35. Unified Huntington's disease rating scale: Reliability and consistency. Mov. Disord. 1996, 11:136-142. Huntington Study Group.
36. Julien C.L., Thompson J.C., Wild S., Yardumian P., Snowden J.S., Turner G., Craufurd D. Psychiatric disorders in preclinical Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 2007, 78:939-943.
37. Kassubek J., Juengling F., Kioschies T., Henkel K., Karitzky J., Kramer B., Ecker D., Andrich J., Saft C., Kraus P., Aschoff A., Ludolph A., Landwehrmeyer G. Topography of cerebral atrophy in early Huntington's disease: A voxel based morphometric MRI study. J. Neurol. Neurosurg. Psychiatry. 2004, 75:213-220.
38. Kassubek J., Juengling F.D., Ecker D., et al. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: A morphometric MRI analysis. Cereb. Cortex. 2005, 15:846-853.
39. Kirkwood S.C., Siemers E., Hodes M.E., et al. Subtle changes among presymptomatic carriers of the Huntington's disease gene. J. Neurol. Neurosurg. Psychiatry. 2000, 69:773-779.
40. Krogias C., Saft C., Strassburger K., Gold R., Norra C., Juckel G., Ninphius D. Hirnparenchym-Sonographie bei depressiven und nicht-depressiven Huntington-Patienten. Nervenarzt 2008, 79(Suppl. 4):372.
41. Krogias C., Strassburger K., Eyding J., Gold R., Norra C., Juckel G., Saft C., Ninphius D. Depression in Huntington's disease correlates with alterations of brainstem raphe depicted by transcranial sonography. J Psychiatry Neurosci. 2010, (submitted).
42. Kuhl D.E., Phelps M.E., Markham C.H., et al. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 1982, 12:425-434.
43. Lambeck J., Niesen W., Zucker B. Substantia nigra hyperechogenicity in Huntington's disease. Akt. Neurologie. 2008, 35(Suppl. 1):S152. abstract.
44. Leeders K.L., Frackowiak R.S.J., Quinn N., Marsden C.D. Brain Energy and Dopaminergic Function in Huntington's disease measured in vivo using Positron Emission Tomography. Movement Disorders 1986, 1:69-77.
45. Lemiere J., Decruyenaere M., Evers-Kiebooms G., et al. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. Acta Neurol. Scand. 2002, 106:131-141.
46. Licklederer C., Wolff G., Barth J. Mental health and quality of life after genetic testing for Huntington disease: A long-term effect study in Germany. Am. J. Med. Genet. 2008, 146A:2078-2085.
47. MacMillan J.C., Quarrell O.W.J. The neurobiology of Huntington's disease. Huntington's disease 1996, 317-357. WP Saunders, London. Second Edition. P.S. Harper (Ed.).
48. Montoya A., Price B.H., Menear M., Lepade M. Brain imaging and cognitive dysfunctions in Huntington's disease. J. Psychiatry Neursci. 2006, 31:21-29.
49. Nance M.A., Myers R.H. Juvenile onset Huntington's Disease-Clinical and research perspectives. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7:153-157.
50. Naumann M., Becker G., Toyka K.V., Supprian T., Rainers K. Lenticular nucleus lesion in idiopathic dystonia detected by transcranial sonography. Neurology 1996, 47:1284-1290.
51. Nopoulos P., Magnotta V.A., Mikos A., Paulson H., Andreasen N.C., Paulsen J.S. Morphology of the cerebral cortex in preclinical Huntington's disease. Am. J. Psychiatry. 2007, 164:1428-1434.
52. Paradiso S., Turner B.M., Paulsen J.S., Jorge R., Ponto L.L., Robinson R.G. Neural bases of dysphoria in early Huntington's disease. Psychiatry Res. 2008, 162:73-87.
53. Paulsen J.S., Ready R.E., Hamilton J.M., Mega M.S., Cummings J.L. Neuropsychiatric aspects of Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 2001, 71:310-314.
54. Paulsen J.S. Functional imaging in Huntington's disease. Exp. Neurol. 2009, 216:272-277.
55. Peinemann A., Schuller S., Pohl C., Jahn T., Windl A., Kassubek J. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 2005, 239:11-19.
56. Phillips W., Shannon K.M., Barker R.A. The current clinical management of Huntington's disease. Mov. Disord. 2008, 23:1491-1504.
57. Postert T., Lack B., Kuhn W., Jergas M., Andrich J., Braun B., Przuntek H., Sprengelmeyer R., Agelink M., Büttner T. Basal ganglia alterations and brain atrophy in Huntington's disease depicted by transcranial real time sonography. J. Neurol. Neurosurg. Psychiatry. 1999, 67:457-462.
58. Quarrel O., Harper P.S. The clinical neurology of Huntington's disease. Huntington's disease 1991, 37-80. WB Saunders, London. P. Harper (Ed.).
59. Rosas H.D., Koroshetz W.J., Chen Y.I., Skeuse C., Vangel M., Cudkowicz M.E., Caplan K., Marek K., Seidman L.J., Makris N., Jenkins B.G., Goldstein J.M. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology 2003, 60:1615-1620.
60. Rosas H.D., Salat D.H., Lee S.Y., Zaleta A.K., Pappu V., Fischl B., Greve D., Hevelone N., Hersch S.M. Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain 2008, 131:1057-1068.
61. Rosenblatt A., Liang K.Y., Zhou H., Abbott M.H., Gourley L.M., Margolis R.L., Brandt J., Ross C.A. The association of CAG repeat length with clinical progression in Huntington's disease. Neurology 2006, 66:1016-1020.
62. Saft C., Kosinski C.M., Landwehrmeyer G.B. Progress in premanifest and manifest diagnostics in Huntington's disease. Akt. Neurol. 2009, 36:506-523.
63. Sánchez-Pernaute R., Künig G., del Barrio Alba A., de Yébenes J.G., Vontobel P., Leenders K.L. Bradykinesia in early Huntington's disease. Neurology 2000, 54:119-125.
64. Seidel G., Kaps M., Gerriets T., Hutzelmann A. Evaluation of the ventricular system in adults by transcranial duplex sonography. J. Neuroimaging. 1995, 5:105-108.
65. Slaughter J.R., Martens M.P., Slaughter K.A. Depression and Huntington's disease: Prevalence, clinical manifestations, etiology and treatment. CNS Spectr. 2001, 6:306-326.
66. Sprengelmeyer R., Young A.W., Calder A.J., et al. Loss of disgust Perception of faces and emotions in Huntington's disease. Brain 1996, 119:1647-1665.
67. Stober T., Wussow W., Schimrigk K. Bicaudate diameter-The most specific and simple CT parameter in the diagnosis of Huntington's disease. Arch. Neurol. 1996, 53:1293-1296.
68. Walker F.O. Huntington's disease. Lancet. 2007, 369:218-228.
69. Walter U., Niehaus L., Probst T., Benecke R., Meyer B.U., Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003, 60:74-77.
70. Walter U., Dressler D., Wolters A., Probst T., Grossmann A., Benecke R. Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 2004, 63:504-509.
71. Walter U., Krolikowski K., Tarnacke B., Benecke R., Czlonkowska A., Dressler D. Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology 2005, 64:1726-1732.
72. Walter U., Behnke S., Eyding J., Niehaus L., Postert T., Seidel G., Berg D. Transcranial brain parenchyma sonography in movement disorders: State of the art. Ultrasound Med. Biol. 2007, 33:15-25.
73. Walter U., Prudente-Morrisey L., Herpertz S.C., Benecke R., Hoeppner J. Relationship of brainstem raphe echogenicity and clinical findings in depressive states. Psychiatry Res. 2007, 155:67-73.
74. Weeks R.A., Picini P., Harding A.E., et al. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 1996, 40:49-54.
75. Weindl A., Conrad B. Chorea. Bewegungsstörungen 2005, 197-211. Georg Thieme Verlag, Stuttgart, New York. Second Edition. A. Ceballos-Baumann, B. Conrad (Eds.).
76. Wexler N.S., Lorimer J., Porter J., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. PNAS (USA). 2004, 101:3498-3503.
77. Young A.B., Greenamyre J.T., Hollingsworth Z., et al. NMDA receptor losses in putamen form patients with Huntington's disease. Science 1988, 241:981-983.
78. Zweig R.M., Ross C.A., Hedreen J.C., Peyser C., Cardillo J.E., Folstein S.E., Price D.L. Locus coeruleus involvement in Huntington's disease. Arch. Neurol. 1992, 49:152-156.